Hypothesis

We propose that the age‑related loss of circadian HDAC3 activity in mesenchymal stromal cells (MSCs) drives the inflammatory degenerative niche that impairs hematopoiesis, and that pharmacologically restoring HDAC3 rhythmicity in aged MSCs will re‑establish circadian niche signaling, reduce stromal inflammation, and improve erythropoietic output.

Mechanistic Basis

Circadian HDAC3 normally deacetylates histones at promoters of niche‑supporting genes (e.g., Scf, Cxcl12, Angpt1) during the active phase, fostering a chromatin state that supports rhythmic secretion of these factors. In aged MSCs, HDAC3 expression becomes arrhythmic and its enzymatic activity declines, leading to hyperacetylated histones, sustained NF‑κB signaling, and elevated secretion of IL‑6 and TNF‑α. This creates a pro‑inflammatory niche that disrupts the circadian entrainment of hematopoietic stem and progenitor cells (HSPCs), blunting the daytime peak of DNA synthesis observed in young individuals [5]. Restoring HDAC3 activity should therefore re‑synchronize the epigenetic clock of MSCs, normalize niche factor secretion, and reinstate the temporal coordination of hematopoiesis.

Testable Predictions

1. Aged MSCs exhibit loss of HDAC3 protein oscillation and reduced deacetylase activity compared with young MSCs.
2. Pharmacological activation of HDAC3 (e.g., via NAD+‑boosting agents that enhance SIRT1‑HDAC3 coupling or selective HDAC3 agonists) applied at the circadian time corresponding to the active phase will restore rhythmic acetylation of histone H3 at niche‑gene promoters.
3. Restored HDAC3 rhythmicity will decrease MSC‑derived IL‑6/TNF‑α secretion and increase rhythmic SCF and CXCL12 release.
4. Co‑culture of HDAC3‑treated aged MSCs with young HSPCs will rescue the circadian variation in HSPC DNA synthesis and increase erythroid colony‑forming unit‑erythroid (CFU‑E) output.
5. In vivo, timed HDAC3 activation in aged mice will ameliorate geriatric anemia, evidenced by higher reticulocyte counts and improved hemoglobin levels, without altering intrinsic HSPC clock gene expression.

Experimental Approach

• In vitro: Isolate MSCs from young (3 mo) and aged (24 mo) mice. Confirm HDAC3 protein levels by Western blot across 24 h cycles. Treat aged MSCs with nicotinamide riboside (NR) or a selective HDAC3 activator timed to ZT6. Measure histone H3K9 acetylation at Scf/Cxcl12 promoters via ChIP‑qPCR, cytokine secretion by ELISA, and assess niche support using HSPC CFU‑E assays under circadian conditions.
• In vivo: Administer NR or HDAC3 activator to aged mice via timed intraperitoneal injections (ZT6 daily for 4 weeks). Controls receive vehicle. Monitor peripheral blood reticulocytes, hemoglobin, and serum cytokines. Perform bone marrow immunofluorescence for MSC markers and HDAC3 localization. Examine HSPC cell‑cycle status via Ki‑67/BrdU incorporation at ZT2 and ZT14.

Potential Outcomes and Falsifiability

If HDAC3 activation restores rhythmic niche factor secretion and improves erythropoiesis as predicted, the hypothesis is supported. Conversely, if HDAC3 activation fails to modify MSC acetylation patterns, does not reduce inflammatory cytokine output, or does not rescue circadian HSPC DNA synthesis and erythroid output despite proper drug timing, the hypothesis is falsified. Additionally, if intrinsic HSPC clock genes (e.g., Bmal1, Per2) show no change yet hematopoiesis improves, this would reinforce the niche‑centric mechanism proposed.